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adverse events. Main Results: The number of CD34+ cells in the 
leukapheresis products were similar in the two groups: the geo- 
metric mean number of CD34+ cells was 1.73 x 10^6/kg in the 
once-daily group and 2.08 x 10^6/kg in the divided-dose group 
(P=.0.37). The geometric mean number of TNCs in the products 
was 6.43 x 10^8/kg in the once-daily group and 6.35 x 10A8/kg in 
the twice-daily group (P=0.87). Although the median total doses 
of analgesic drug were similar in both groups (6.35mg/kg vs 
7.69mg/kg acetoaminophen, P=0.79), the donors in the once-dally 
group experienced significantly less pain than twice-daily group 
(median AUS of VAS; 21.5 vs 52.5 ram*days, P=0.043). The inci- 
dences and severities of adverse vents other than pain were simi- 
lar in both groups. Conclusions: In comparison with two-divided 
dose regimen, once daily injection of 400btg/m^2 of G-CSF is 
equally effective for allogeneic PBSC nmbilization and associated 
with less pain. Taldng into account of donor's convenience, once- 
daily regimen is preferable to twice-daily regimen. 
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IN VITRO PRIMING AND EXPANSION OF CMV-SPECIFIC THI AND 
TCI T CELLS FROM NAIVE CORD BLOOD LYMPHOCYTES BY AUTOL- 
OGOUS DENDRITIC CELLS 
S:abolcs, P., Ma1~i, L.; Reese, 3/14 I~;rtzbe'rg, ft.; Par~e, K. Dulee Uni- 
versity, Pediatric BMT Progr, zm, Dm'taam, NC. 
BACKGROUND: Adoptive transfer of CMV specific cytoto~c T 
cells (CTL) expanded in vitro from donor memory cells have reduced 
CMV disease in the allogeneic BMT setting. However, dais approach 
has not been feasible in the unrelated cord blood transplant (uUCBT) 
setting as cord blood contains naive, unprimed T ceils. YVe developed 
an in vitro protocol to prime and expand CMV-specific CTL from 
cord blood. METHODS: Monocytes from 6 UCB units were cul- 
tured with GM-CSF/IL-4 for 6 days to generate immature Des 
(Mo/DCs). Autologous UCB lymphocytes were primed either with 
CMV-lysate-pulsed Mo/DCs (CMV+) or as negative controls 
unpulsed (CNIV-) or sham Iysate loaded Mo/DCs. Prior to priming 
CMV +/- loaded immature DC received 12h maturation signals 
(TNFc~+PGE2) inducing expression of CDS0, CD86 and HLA mol- 
ecules. For restimulation and expansion of CTL cultures DC were 
generated from CD34+ cells cultured in SCF/Flt-3L/GM-CSF/IL- 
4 for 14 ~ 21days and GM-CSF/IL-4 for 6days. DCs and responder 
lymphocytes were cultured in the presence of low dose IL-2 
(10IU/ml), IL-7, and IL-12 to skew the priming and expansion 
towards ThI and Tcl cells. CTL cultures were -stimulated weeldy 
for 5~ 7 weeks. After the 4th week CD3+ T cells were tested weeHy 
by ic FACS analysis for CMV-specific IFNy, TNFc( secretion. 
CMV-specific cytotoxicity was tested by LDH release assay on 
CMV+, CMV or sham lysate loaded autologous Mo/DC. 
RESULTS: CMV+ cultures expanded significantly more (3.5 ~ 13.39 
tbld) than CMV- cultures (0.65 ~ 7.8 fold) despite identical cytokine 
milieu. There was a preferential expansion of CD45RA-/RO+ 'mem- 
ory' T cells in CMV+ cultures compared to CMV- cultures (CMV+: 
66~86% of CD3+ versus CMV-: 30 ~ 46% of CD3+. CMV-specific 
interferon gamma produchag T cells were 4.7 ~ 35.3 % (mean: 16.1%) 
in CMV+ cultures and 0 ~ 2% (mean 0.5%) of CD3+ in CMV-cul 
rares respectively (p=0.025) witla bo h CD4+ (Thl) and CD8+ (TcI) 
T cells contributing. CMV-specific CTtOto.-dcity at10:1 E:T ratio was 
31 ~ 48 % from CMV+ cultures and 10~ 13% from CMV- or sham 
lysate cultures. CONCLUSION: This dataset is the first to our 
knowledge to demonstrate the generation of CMV-specific CTLs 
that were primed and expanded in vitro from naive umbilical cord 
lymphocytes. This approach may lead to effective clinical strategies 
against CMV infection in the uUCB transplantation setting. 
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UPREGULATION OF THE EXPRESSION OF MOLECULES INVOLVED IN 
ALLORECOGNITION: IMPLICATIONS FOR POTENTIATING THE MIXED 
LYMPHOCYTE REACTION PRIOR TO SELECTIVE ALLOREACTIVE T 
CELL DEPLETION 
Davies, ff.K.; Koh, M.B.; Prentice, H.; Lowdell, 3/I.FV. Depa;~tment of 
Haematology, Royal Free Hospital, London, United Kingdom. 
Various mechanisms ofselective depletion of alloreactive T cells in 
haematopoietic stem ceil (HSC)grafts have been described: all 
depend upon the stimulation of donor alloreactive cells byrecipient 
cells in a unidirectional mixed lymphocyte reaction (MLR). In the 
HLA identical donor setting, stimulation of alloreactive donor cells in 
a standard MLR often fails to occur: in this setting amodification of 
the MLR with cytoldne pre-treatment of stimulator cells has been 
described. We investigated the effect of two strategies designed to 
potentiate the MLR on expression of cell surface molecules impor- 
tant in allostimulation. The expression of adhesion molecules 
(CD1 la, CD54(ICAM I)), co-stimulatury molecules (CD80 and 
CD86) and HLA class I and Class II molecules were measured by 
flow cytometry after stimulation of monocytes and T cells with 
TNF-alpha, IL4 and/or gamma-interferon f r 24 and 48 hours. Sim- 
ilar observations were made of T cells stinmlated with immobilized 
nfitogenic OKT3 +/- agonistic anti-CD28. The e~pression of CD178 
(Fas ligand) in these cells was also determined at 24 and 48 hours. 
Effective upregulation of molecules involved in allorecognition 
occurred with all three cytokines on monocytes and with g-IFN and 
TNF a on T cells. Use of immobilised OKT3 caused much greater 
increases in eNaression of similar molecules on T ceils and an increase 
in the proportion of T ceils expressing FAS ligand. The addition of 
anti-CD28 to OKT3 had no additional benefit in upregulation of 
these molecules. Results are summarised below (NT=Not Tested). 
Both strategies may enhance alloantigen presentation i  the HLA 
identical situation and facilitate the activation (and subsequent 
removal) of alloreactive cells in HSC grafts. The increase in the pro- 
portion ofT ceils expressing FAS ligand seen with OKT3 stimulation 
may enhance FAS-mediated apoptosis of alloreactive cells. We are 
currendy investigating the use of both techniques in modifications of
the MLR as part of our selective allodepletion research programme. 
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TIME-TEMPERATURE STUDY OF CELL SURVIVAL IN BONE MARROW 
(BM) AND BLOOD HEMATOPOIETIC PROGENITOR CELL (HPC) GRAFTS 
Rosenthal, H.S/; Miller, ft.:; Hicks, AI.1; Weisdo~f, D/; Waller, E.K/ 
i. Emmy University, Atlanta, GA; 2. U~iversity of Mimzesota, 3/lin- 
neapolis, 3/[~ 
Background: Standard practice in BM and blood HPC trans- 
plants facilitated by the NMDP is to ship BM HPC grafts at 
room temperature and blood HPC grafts at 4°C. There is lim- 
ited information regarding the effect of storage conditions on 
the content of cell subsets in the graft. We undertook a 
prospective study of the effect of time and temperature on the 
content of viable CD34+ cells, T-cell, B-cell, NK cells and den- 
dritic cell subsets in blood and BM HPC grafts. Method: Small 
aliquots of blood (N=4) and BM (N=5) HPC grafts from 
patients harvested at two transplant centers were obtained from 
quality control samples discarded from the processing laborato 
ries. The number of viable nucleated cells was determined by 
fluorescent microscopy following staining with ethidium bro- 
mide and acridine orange and storage for 24, 48 or 72 hours at 
4°C or RT. The content of CD34+ cells, T-cells, B-cells, NK 
cells and dendritic cell subsets was determined using flow 
cytometry and propidium iodide to electronically exclude non- 
viable cells. Results: BM grafts had better overall cell viability 
during storage than bIood HPC grafts at both temperatures. 
The median number of viable CD34+ cells in BM HPC grafts 
was stable at 4°C and RT during 48 hours storage then 
declined to 50% and 29% of the initial values, respectively, 
after 72 hours. In contrast, there was a steady decline in the 
numbers of viable CD34+ cells in blood HPC grafts throughout 
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the 72-hour period, without significant differences between 4°C 
and RT storage (29% and 20% initial values, respectively). T- 
cell content remained stable at both temperatures and in blood 
and BM HPC grafts during 3 days storage. A marked decline in 
the number of viable type 2 dendritic cell progenitors (DC2p) 
was seen in the first 24 hours in blood HPC grafts during stor- 
age at both 4°C and RT (27% and 24% and of initial values, 
respectively), while content of DC2p in BM HPC grafts 
remained stable up to 48 hours (60% and 70% initial values at 
4°C and RT, respectively). Conclusions: Storage at 4°C did not 
impair the content of viable CD34+ cells or T-cells in blood or 
BM ItPC grafts, and was superior to storage at RT in preserv- 
ing the overall viability of blood HPC grafts. DC2p are particu- 
larly sensitive to storage, and prolonged transit times may 
impact the content of these immuno-regulatory cells in trans- 
plants. 
Analyses at te t  72 hot.s: Median 4 degrees R~om Te p 4 degrec~ ] Room letup 
I 
pelcentages of initial values BM HPC BM HPC Blood HPC [ Blood HPC 
Viable CD34+ 50% 29% 29% ] 20q 
Viable CD3+ 51% 63% 77% ] 27% 
Viable DC2p 54% 31% 8% ! I1~ 
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OUTCOME OF PATIENTS TREATED WITH HIGH DOSE MELPHALAN 
WITH OR WITHOUT TBI FOLLOWED BY CD34 SELECTED STEM CELL 
RESCUE USING THE BAXTER ISOLEX 3001 
B'roun, E.R.; Sigmund, D.; Essell, J.; Tievne~, C. Jewish Hospital, 
Cincimmti, OH. 
We treated 24 patients with multiple myeloma with high dose 
melphalan +/- TBI using CD34 selection between 1/99 and 7/01. 
Patients were treated as part of initial therapy following 4 cycles of 
VAD in most cases. Mobilization was with either VP16/ 
cyclophosphamide (5) or cyclophosphamide (19) followed by G- 
CSF. Patients then underwent 20L apheresis on a COBE Spectra 
with a collection goal of 6.5 x 106 CD34+ cells/kg. CD34 selection 
with the BAXTER Isolex 300i was carried out on the pheresis 
product with 1.5 x 106 CD34+cells/kg stored as backmp. Patients 
underwent a median of 2 phereses (range 1-6) with a mean collec- 
tion of 24.1 x 10 6CD34+ cells/kg (range 6.9-57.8). Following 
selection, a mean of 10.4 x 106 CD34+ cells/kg were infused at 
time of transplant. Post infusion recovery of WBC to an ANC 
>500/uL occurred in a mean of 26.9d (range 13-7 l d) and platelets 
to >20, 000/uL at 79.3d (range 15-360d). 4 patients expired prior 
to recovery of platelets and one remains platelet ransfusion 
dependent 3 years post transplant. There was one early death due 
to aspiration pneumonia. Overall 10 pts have expired, cause of
death: progressive disease 6, pneumonia 2, sepsis 2. The remain- 
ing 14 pts are alive, 3 in relapse and 11 (46%) in remission. Nine 
patients have relapsed (38%). Mean follow-up for the entire 
group is 18.4 mos. For the 11 pts in remission the median time 
frmn transplant is 18 mos (14-41 mos). CD34 selection led to pro 
longed recovery of granulocytes and platelets. Longer follow-up is 
needed to assess the durability of the remissions. 
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ENGRAFTMENT AND PRODUCTION OF MESENCHYMAL COLONY 
FORMING CELLS (M-CFC) IN VITRO 
La Russa, ~:F.; Lee, M.; Price, S.; Sarah, H.; Mille1", A.; Rozm~s, M.; 
~Veiner, R. TULANE UNIVERSITY CANCER CENTER, NEW 
ORLEANS, L4. 
A 2-stage stromal cell culture system that supports production of 
early hematopoietic progenitor cells (LTCIC, CFU-BLAST) was 
evaluated tbr mesenchymal progenitor cells, M-CFC. Stage-1 was 
initiated by culturing female bone marrow low density" mononu- 
clear cells (LDMNC) for 2 weeks. At day 0, 2-week old female 
recipient stromal colonies were lethally irradiated (25Gy) to elimi- 
nate endogenous M-CFC(XX) and then seeded with 2.5X10 ~ 
LDMNC from male-donor bone marrow containing only 27+_3 
M-CFC(XY). Engraftment and subsequent production of male 
donor-derived M-CFC (XY) activity was measured weekly by sec- 
ondary plating of both non-adherent and adherent cell fractions 
derived from female-recipient stromal colonies that were initially 
seeded with male donor bone marrow LDMNC. Fluorescence in
situ-hybridization (FISH) with DNA probes DXZI from the X- 
chromosome centromere region and the DYZI from the Yql2 
region was performed on representative s condary M-CFC 
derived stromal colonies at each week. At week-1 there was >7X 
expansion of M-CFC(XY) activity in both adherent and non- 
adherent stromal cell fractions as compared to the original 27+3 
M-CFC(XW) added at day 0. Most of the M-CFC(XY) activity 
localized within the female recipient adherent stromal cell fraction 
contained 187+-17 M-CFC(XY)/plate and formed individual stro- 
mal colonies with surface area r nge: 4rome; <16 mm 2. In addition, 
there were 20+2 M-CFC(XY)/plate, that were more proliferative 
and formed larger colonies with surface area range: >16 ram-'; < 30 
mm~, and 10+-2 M-CFC(X~/plate with the highest proliferative 
potential forming colonies with surface area: >30 mm 2. At week-2, 
ahnost all of the M-CFC(XY) remained in direct-contact with the 
female recipient adherent stromal cell fraction and continued to
further expand to 490+50 M-CFC(XY)/plate. The plating effi- 
ciency of mesenchymal progenitor cells at 3-weeks was >90% with 
a yield of 1, 150+-150 M-CFC (XY) / plate, but their proliferative 
index was reduced to form smaller stromal ceil colonies with sur- 
face area 4mm-'; <16 nun 2, and 13,600+-770 stromal cell clusters 
(XY)/plate. These studies show" that lethally irradiated female 
recipient mesenchymal/stromal cell colonies upport the engraft- 
ment of pre-clonogenic mesenchymal stenrcells. 
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FLOW CYTOMETRIC ANALYSIS OF CELLULAR DIFFERENTIATION 
ARREST IN MYELODYSPLASTIC SYNDROME 
S,beJw~an, M.; Dicke, K.; Palmer, D. Stem Cell Lab, A'dington Cance'~" 
Center, Arlington, T2~ 
CD33 has been shown to be a marker for cellular immaturity at 
the promyelocyte l vel. One of the hematological findings in 
myelodysplastic syndrome (MDS) is cellular differentiation (mare- 
ration) arrest. The purpose of this study was to determine the 
diagnostic utility of flow cytometry in confirming the clinical find 
ings in MDS. Our study analyzed the percentage of CD33+ and 
CD 33 +/CD 11 c+ cells by flow cytometry in 18 patients clinically 
diagnosed with MDS. Controls consisted of 30 patients who were 
hematologically normal. Normal ranges for CD33+ and 
CD33+/CD11c+ were 19-41% and 58-80%, respectively. All 18 
MDS patients were found to have a percentage of CD33+ cells in 
excess of 41% (43-68%) and a percentage of CD33+/CDllc+ 
cells less than 58% (31-56%), clearly demonstrating anaccumula- 
tion of ceils at the promyelocyte l vel at the expense of mature 
cells, demonstrating maturation arrest. We also found a slight 
increase in CD34+/CD33+ cells (from 0.5% to 0.73 %), therefore 
a prelude for excess blast cells and the possible transformation f 
MDS into acute myelocytic leukemia (AML). We conclude that 
flow cytometry is a promising tool in assisting the clinician in 
diagnosing MDS and its progression. 
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MOBILIZATION OF PERIPHERAL BLOOD PROGENITOR CELLS (PBPC) 
WITH COMBINATION OF CYTORINES IN AUTOLOGOUS AND ALLO- 
GI:NEIC PEDIATRIC TRANSPLANT 
Guev~'a, J.A.; Mm'tinez, C.A.; Barrios, N.J. Pediatrics, Univer,'ity of 
Puel"to Rico Sc,%ol of MedMne, San J.an, Pue'~to Rico. 
Background:Clinical trials to mobilize PBPC for antologous 
and allogeneic harvesting prior to high dose chemotherapy / 
radiotherapy include chemotherapy, eytokines, or chemotherapy 
combined with cytokines. PBPC mobilized by G CSF or GM- 
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